ResMed [RMD] vs Hologic [HOLX] Detailed Stock Comparison
ResMed
NYSE
Loading...
Hologic
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: ResMed wins in 12 metrics, Hologic wins in 7 metrics, with 0 ties. ResMed appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | ResMed | Hologic | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 30.68 | 27.76 | Hologic |
| Price-to-Book Ratio | 7.15 | 3.07 | Hologic |
| Debt-to-Equity Ratio | 14.27 | 52.09 | ResMed |
| PEG Ratio | 28.32 | 14.17 | Hologic |
| EV/EBITDA | 22.45 | 12.43 | Hologic |
| Profit Margin (TTM) | 27.22% | 13.79% | ResMed |
| Operating Margin (TTM) | 33.87% | 25.48% | ResMed |
| EBITDA Margin (TTM) | 33.87% | 25.48% | ResMed |
| Return on Equity | 25.86% | 11.38% | ResMed |
| Return on Assets (TTM) | 14.02% | 6.69% | ResMed |
| Free Cash Flow (TTM) | $1.29B | $1.15B | ResMed |
| Dividend Yield | 0.63% | N/A | N/A |
| 1-Year Return | 31.08% | -18.63% | ResMed |
| Price-to-Sales Ratio (TTM) | 8.30 | 3.68 | Hologic |
| Enterprise Value | $42.33B | $15.52B | ResMed |
| EV/Revenue Ratio | 8.23 | 3.84 | Hologic |
| Gross Profit Margin (TTM) | 59.33% | 56.32% | ResMed |
| Revenue per Share (TTM) | $35 | $18 | ResMed |
| Earnings per Share (Diluted) | $9.50 | $2.41 | ResMed |
| Beta (Stock Volatility) | 0.77 | 0.49 | Hologic |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
ResMed vs Hologic Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| ResMed | 1.33% | 1.68% | 10.64% | 16.79% | 19.01% | 24.26% |
| Hologic | 0.19% | 1.34% | 4.87% | 21.15% | 4.32% | -5.13% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| ResMed | 31.08% | 18.30% | 60.60% | 408.33% | 804.72% | 1,617.48% |
| Hologic | -18.63% | -6.75% | 1.87% | 60.33% | 361.11% | 493.89% |
Performance & Financial Health Analysis: ResMed vs Hologic
| Metric | RMD | HOLX |
|---|---|---|
| Market Information | ||
| Market Cap | $42.73B | $14.88B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 1,344,910 | 1,830,700 |
| 90 Day Avg. Volume | 1,008,590 | 1,903,103 |
| Last Close | $283.90 | $68.06 |
| 52 Week Range | $199.92 - $293.08 | $51.90 - $84.67 |
| % from 52W High | -3.13% | -19.62% |
| All-Time High | $301.34 (Sep 06, 2021) | $87.88 (May 01, 2023) |
| % from All-Time High | -5.79% | -22.55% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.10% | 0.01% |
| Quarterly Earnings Growth | 0.30% | 0.00% |
| Financial Health | ||
| Profit Margin (TTM) | 0.27% | 0.14% |
| Operating Margin (TTM) | 0.34% | 0.25% |
| Return on Equity (TTM) | 0.26% | 0.11% |
| Debt to Equity (MRQ) | 14.27 | 52.09 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $40.74 | $21.79 |
| Cash per Share (MRQ) | $8.26 | $8.47 |
| Operating Cash Flow (TTM) | $1.75B | $1.07B |
| Levered Free Cash Flow (TTM) | $1.21B | $760.11M |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.63% | N/A |
| Last 12-Month Dividend | $1.59 | N/A |
Valuation & Enterprise Metrics Analysis: ResMed vs Hologic
| Metric | RMD | HOLX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 30.68 | 27.76 |
| Forward P/E | 28.32 | 14.17 |
| PEG Ratio | 28.32 | 14.17 |
| Price to Sales (TTM) | 8.30 | 3.68 |
| Price to Book (MRQ) | 7.15 | 3.07 |
| Market Capitalization | ||
| Market Capitalization | $42.73B | $14.88B |
| Enterprise Value | $42.33B | $15.52B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 8.23 | 3.84 |
| Enterprise to EBITDA | 22.45 | 12.43 |
| Risk & Other Metrics | ||
| Beta | 0.77 | 0.49 |
| Book Value per Share (MRQ) | $40.74 | $21.79 |
Financial Statements Comparison: ResMed vs Hologic
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | RMD | HOLX |
|---|---|---|
| Revenue/Sales | $1.29B | $1.01B |
| Cost of Goods Sold | $525.33M | $628.00M |
| Gross Profit | $766.41M | $377.30M |
| Research & Development | $83.94M | $61.50M |
| Operating Income (EBIT) | $426.27M | $37.90M |
| EBITDA | $478.18M | $121.70M |
| Pre-Tax Income | $417.69M | $-28.50M |
| Income Tax | $52.65M | $-11.10M |
| Net Income (Profit) | $365.04M | $-17.40M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | RMD | HOLX |
|---|---|---|
| Cash & Equivalents | $932.71M | $1.43B |
| Total Current Assets | $3.21B | $3.21B |
| Total Current Liabilities | $940.52M | $989.70M |
| Long-Term Debt | $801.12M | $2.47B |
| Total Shareholders Equity | $5.55B | $4.62B |
| Retained Earnings | $5.78B | $3.03B |
| Property, Plant & Equipment | $1.39B | $939.80M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | RMD | HOLX |
|---|---|---|
| Operating Cash Flow | $430.90M | $28.40M |
| Capital Expenditures | $-20.80M | $-24.70M |
| Free Cash Flow | $554.87M | $129.20M |
| Debt Repayment | $0 | $-10.20M |
| Common Stock Repurchase | $-75.03M | $-200.00M |
Short Interest & Institutional Ownership Analysis
| Metric | RMD | HOLX |
|---|---|---|
| Shares Short | 9.38M | 5.15M |
| Short Ratio | 11.59 | 2.16 |
| Short % of Float | 0.07% | 0.03% |
| Average Daily Volume (10 Day) | 1,344,910 | 1,830,700 |
| Average Daily Volume (90 Day) | 1,008,590 | 1,903,103 |
| Shares Outstanding | 146.90M | 231.73M |
| Float Shares | 145.55M | 220.31M |
| % Held by Insiders | 0.01% | 0.01% |
| % Held by Institutions | 0.65% | 1.04% |
Dividend Analysis & Yield Comparison: ResMed vs Hologic
| Metric | RMD | HOLX |
|---|---|---|
| Last 12-Month Dividend | $1.59 | N/A |
| Last 12-Month Dividend Yield | 0.63% | N/A |
| 3-Year Avg Annual Dividend | $1.60 | N/A |
| 3-Year Avg Dividend Yield | 0.23% | N/A |
| 3-Year Total Dividends | $4.79 | N/A |
| Ex-Dividend Date | Feb 13, 2025 | N/A |